title: [Variation of cytokines with administration of chemotherapeutic and immuno-therapeutic drugs for colorectal cancer].
abstract: Systemic and local immunological responses were studied in patients with or without preoperative administration of chemotherapeutic and/or immunotherapeutic drugs for colorectal cancer. The plasma TGFbeta and other cytokines such as IL-2, IL-4, IL-6, IL-10, IL-12, IFN-gamma in the supernatant fluid of culture of peripheral blood mononuclear cell (PBMC) and regional lymph node were measured by the ELISA method. A systemic response of cytokines was as follows: the production of plasma TGFbeta increased in many cases by chemotherapeutic drugs with a significant elevation of the mean production. Productions of IFN-gamma, IL-2, IL-12 in the supernatant fluid of culture of PBMC increased in many cases by immunotherapeutic drugs, and that of IL-4, IL-6 increased in many cases by chemotherapeutic drugs. A local response of cytokines was as follows: the production of IL-2 by immunotherapeutic drugs was greater than that without immunotherapeutic drugs whereas the production of IL-10 by immunotherapeutic drugs was smaller than that without immunotherapeutic drugs.
authors.affiliation: Dept. of Surgery, Fujita Health University School of Medicine.
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Katsuno
authors.forename: Koutaro
authors.initials: K
authors.lastname: Maeda
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Utsumi
authors.forename: Tsunekazu
authors.initials: T
authors.lastname: Hanai
authors.forename: Harunobu
authors.initials: H
authors.lastname: Sato
authors.forename: Koji
authors.initials: K
authors.lastname: Masumori
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Koide
authors.forename: Masahisa
authors.initials: M
authors.lastname: Matsumoto
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000628:therapy*; D016207:Cytokines / Q000096:biosynthesis*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D016753:Interleukin-10 / Q000096:biosynthesis; D018664:Interleukin-12 / Q000096:biosynthesis; D007376:Interleukin-2 / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D011509:Proteoglycans / Q000494:pharmacology* / Q000627:therapeutic use; D005641:Tegafur / Q000494:pharmacology* / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000097:blood; D014498:Uracil / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D007376:Interleukin-2; D015850:Interleukin-6; D011509:Proteoglycans; D016212:Transforming Growth Factor beta; D016753:Interleukin-10; D005641:Tegafur; D018664:Interleukin-12; D015847:Interleukin-4; C010770:polysaccharide-K; D014498:Uracil; D007371:Interferon-gamma